Abeona Therapeutics Incの配当利回り
Abeona Therapeutics Incの配当利回りは何ですか。
Abeona Therapeutics Incの配当利回りは0.00%です。
配当利回りの定義は何ですか。
配当利回りは、過去1年間の1株当たり配当金と1株の時価での配当金の割合をパーセントで表したものです。
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
NASDAQのセクタHealth Careにおける配当利回りの企業と比べるAbeona Therapeutics Inc
Abeona Therapeutics Incは何をしますか。
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Incと類似の配当利回り
- Abeona Therapeutics Incの配当利回りは0.00%です。
- The Monks Investment Trust Plcの配当利回りは0.00%です。
- Crestwood Equity Partners LPの配当利回りは0.00%です。
- Veritas (India)の配当利回りは0.00%です。
- Pacific Horizon Investment Trust Plcの配当利回りは0.01%です。
- AVI Global Trust plcの配当利回りは0.01%です。
- Artemis Alpha Trust plcの配当利回りは0.01%です。